Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
Clinical Trial
A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
This study will see whether two injectable anti-HIV medications are as effective as a specific oral medication regimen for HIV-positive adults.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 or older who have never taken anti-HIV medications 2. HIV viral load count at least 1000 EXCLUSION: 1. Certain medical conditions not allowed by the study, and labs outside of ranges allowed by the study 2. Patient has received medications or treatments not allowed within specific timeframes by the study
RESEARCH. INNOVATION. DISCOVERY.